Golestan University of Medical Sciences Repository

Comparison of glycemic excursion in patients with new onset type 2 diabetes mellitus before and after treatment with repaglinide

Hezarkhani, S. and Bonakdaran, S. and Rajabian, R. and Shahini, N. and Marjani, A. (2013) Comparison of glycemic excursion in patients with new onset type 2 diabetes mellitus before and after treatment with repaglinide. Open Biochemistry Journal, 7 (1). pp. 19-23. ISSN 1874091X (ISSN)

[img]
Preview
PDF - Published Version
Download (242kB) | Preview

Abstract

Due to industrialization and sedentary life, incidence of type 2 diabetes (DM2) is increasing seriously. Repaglinide is a glucose reducing agent that predominantly reduces post-prandial glucose. Continuous glucose monitoring system (CGMS) monitors blood glucose excursions over a 3-day period. CGMS can be used as a therapeutic and diagnostic instrument in diabetics. There are not enough studies about using CGMS in DM2. The aim of this study was to determine the blood glucose excursions in patients with new onset of DM2. 10 patients with new onset of DM2 were entered to this study. As the first therapeutic management, patients received diabetic diet and moderate exercise for 3-weeks, if they did not achieve blood glucose goal (Fasting blood glucoser (FBG) <120mg/dl, 2-hour postprandial blood glucose (2hpp) <180mg/dl), were considered to undergo 3-days CGMS at baseline and after 4-weeks on Repaglinide (0.5mg three times before meals). Mean excursions of blood glucose were not different at the onset and at the end of treatment (6±4.05 VS 7.6±5.2 episodes, P=0.49). There were also no significant differences between mean duration of hypoglycemic episodes (zero VS 5.1±14.1 hours, P =0.28) and hyperglycemic episodes before and after therapy (7.6±5.2 VS 5.7±4.1, P=0.42), but mean hyperglycemia duration was significantly reduced at the end of therapy (21±26.17 VS 57.7±35.3, P=0.001). Patients experienced a mean of 0.3±0.67 episodes of hypoglycemia after therapy showed no significant difference before it (P =0.19). Mean FBG (with CGMS) was significantly lower after therapy than before it (142.9±54.31 VS 222.9±82.6, P <0.001). This study showed the usefulness of CGMS not only as a diagnostic but also as an educational and therapeutic tool that in combination with Repaglinide (with the lowest effective dose and duration) can significantly reduce FBG and glycemic excursions in DM2 patients and hypoglycemic events are low. © Hezarkhani et al.

Item Type: Article
Additional Information: Unmapped bibliographic data: LA - English [Field not mapped to EPrints] J2 - Open Biochem J. [Field not mapped to EPrints] AD - Department of Internal Medicine, Golestan University of Medical Sciences, Gorgan, Iran [Field not mapped to EPrints] AD - Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran [Field not mapped to EPrints] AD - Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran [Field not mapped to EPrints] AD - Gorgan Faculty of Medicine, Department of Biochemistry and Biophysics, Metabolic Disorders Research Center, Gorgan Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Golestan Province, Iran [Field not mapped to EPrints] DB - Scopus [Field not mapped to EPrints]
Uncontrolled Keywords: Continuous glucose monitoring system, Glycemic excursions, Repaglinide, Type 2 diabetes, glucose, repaglinide, adult, article, blood glucose monitoring, clinical article, continouos glucose monitoring system, continouus glucose monitoring system, continuous glucose monitoring system, diabetic diet, drug response, female, glucose blood level, glycemic control, human, hypoglycemia, kinesiotherapy, male, medical device, non insulin dependent diabetes mellitus, priority journal, treatment outcome
Subjects: مقالات نمایه شده محققین دانشگاه در سایت ,Web of Science ,Scopus
موارد کلی
Divisions: معاونت تحقیقات و فناوری
Depositing User: GOUMS
Date Deposited: 19 Apr 2015 07:21
Last Modified: 10 May 2015 05:48
URI: http://eprints.goums.ac.ir/id/eprint/1900

Actions (login required)

View Item View Item